Showing results (421-430 of 537) with videos related to

Sort By:
Pageof 54
RMD Open|November 14, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature researchAndreas Kerschbaumer, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases|February 2, 2012
PAR(2) expression in peripheral blood monocytes of patients with rheumatoid arthritisA Crilly, E Burns, M B Nickdel, et al.
Arthritis and Rheumatism|August 4, 2011
Impaired dendritic cell proinflammatory cytokine production in psoriatic arthritisMark H Wenink, Kim C M Santegoets, John Butcher, et al.
Lancet (London, England)|May 21, 2016
Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trialDuncan Porter, Jurgen van Melckebeke, James Dale, et al.
The Journal of Clinical Investigation|November 24, 1999
A proinflammatory role for IL-18 in rheumatoid arthritisJ A Gracie, R J Forsey, W L Chan, et al.
Annals of the Rheumatic Diseases|November 1, 2016
Differential impact of obesity on the pathogenesis of RA or preclinical models is contingent on the disease statusSeung-Jae Kim, Zhenlong Chen, Abdul B Essani, et al.
Annals of the Rheumatic Diseases|February 11, 2025
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases - a systematic literature review informing the 2024 update of an international expert consensus statementVictoria Konzett, Josef S Smolen, Peter Nash, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 26, 2011
IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone lossMario M Zaiss, Mariola Kurowska-Stolarska, Christina Böhm, et al.
Rheumatology (Oxford, England)|March 16, 2026
Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studiesLaure Gossec, Laura C Coates, Robert B M Landewé, et al.
Lancet (London, England)|July 3, 2015
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialIain B McInnes, Philip J Mease, Bruce Kirkham, et al.
Pageof 54